Market Research Report
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2020
|Published by||Global Markets Direct||Product code||232787|
|Published||Content info||672 Pages
Delivery time: 1-2 business days
|Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2020|
|Published: May 30, 2020||Content info: 672 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes - Pipeline Review, H1 2020, provides an overview of the Type 1 Diabetes (Metabolic Disorders) pipeline landscape.
Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Type 1 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 6, 2, 10, 34, 28, 1, 116, 23 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 1, 1, 31 and 4 molecules, respectively.
Type 1 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.